Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| A-192621 SCHEMBL1030269 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL29551251 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL7465738 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL22404939 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| A-192621 SCHEMBL3982386 | 1.00 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8176298 | 0.97 | EDNRB (0.94) | EDNRBEDNRA | |
| SCHEMBL8189498 | 0.94 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8189503 | 0.94 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8185019 | 0.94 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8180058 | 0.94 | EDNRB (1.00) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888340-B1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2002-07-17 | — | — | EP | claimed |
| US-6124341-A | A DRUG FOR TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, RESTENOSIS FOLLOWING ARTERIAL INJURY, CEREBRAL OR MYOCARDIAL ISCHEMIA OR ATHEROSCLEROSIS; VASODILUTOR | ABBOTT LABORATORIES (US) | 2000-09-26 | — | — | US | claimed |
| EP-4743449-A1 | L-ARGININE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO Pharma (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743450-A1 | L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO Pharma (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743451-A1 | TROMETHAMINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO Pharma (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-20250019370-A1 | L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO PHARMA (FR) | 2025-01-16 | — | — | US | disclosed |
| WO-2025012038-A1 | L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO PHARMA (FR) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025012422-A1 | L-ARGININE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO PHARMA (FR) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025012425-A1 | TROMETHAMINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO PHARMA (FR) | 2025-01-16 | — | — | WO | disclosed |
| US-20250019358-A1 | L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO PHARMA (FR) | 2025-01-16 | — | — | US | disclosed |
| US-12030861-B1 | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | ENYO PHARMA (FR) | 2024-07-09 | — | — | US | disclosed |
| EP-1906987-A4 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | POPULATION COUNCIL INC (US) | 2009-01-28 | — | — | EP | disclosed |
| EP-1906987-A1 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | The Population Council, Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012006-A1 | METHODS AND COMPOSITIONS FOR EMERGENCY CONTRACEPTION USING ENDOTHELIN RECEPTOR ANTAGONISTS | THE POPULATION COUNCIL, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| EP-0888340-B1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6124341-A | A DRUG FOR TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, RESTENOSIS FOLLOWING ARTERIAL INJURY, CEREBRAL OR MYOCARDIAL ISCHEMIA OR ATHEROSCLEROSIS; VASODILUTOR | ABBOTT LABORATORIES (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0991620-A1 | PYRROLIDINE CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0888340-A1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998057933-A1 | PYRROLIDINE CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1997030046-A1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019358-A1 | L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | PHYKPL, BCAT2, AADAT | EDNRB 3601/4885EDNRA 3287/4885 |
| US-20250019370-A1 | L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | PHYKPL, BCAT2, AADAT | EDNRB 3610/4885EDNRA 3313/4885 |
| US-12030861-B1 | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | PHYKPL, BCAT2, AADAT | EDNRB 3610/4885EDNRA 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.